NEWS & INSIGHTS

Glioblastoma

Turning exceptional survival into therapeutic targets: Cure51 and Servier are combining exceptional survivor biology, multi-omics and computational research to identify and validate new therapeutic targets in glioblastoma, an aggressive cancer with limited treatment.

GBM | Servier | Target Discovery | Target Identification

Nicolas-Wolikow-Cure51-Servier-Partnership-Glioblastoma

Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"

Cure51 and Servier aim to uncover mechanisms of survival that could help develop new treatments for glioblastoma patients worldwide.

Sep 30, 2026

Ashley Lakner, CSO: “The partnership with Servier opens new opportunities to identify therapeutic targets for glioblastoma”

Our CSO Ashley Lakner, PhD explains the scientific significance of our new partnership with Servier

Sep 24, 2026

exceptional-glioblastoma-survivors-drug-discovery

How Exceptional Glioblastoma Survivors Could Help Identify New Therapeutic Targets

Discover how studying exceptional glioblastoma survivors and their biology could help identify new therapeutic targets and inform drug discovery.

Sep 23, 2026

Glioblastoma vs. Glioma: the Full Guide to Understanding Glioma, GBM and the Future of Research

Why is Cure51 focusing on glioblastoma?

Sep 22, 2026

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma

Sep 13, 2026

Spatial biology is changing how we understand glioblastoma

Aug 11, 2026

ROSALIND